二级预防药物对恶性肿瘤化疗患者中性粒细胞减少症发生率的影响  

Effect of secondary prophylactics on the incidence of neutropenia in patients undergoing chemotherapy for malignant tumors

作　　者：赖燕辉 黄小琴 梁清海 LAI Yanhui;HUANG Xiaoqin;LIANG Qinghai(Department of Oncology,Boluo People’s Hospital,Huizhou Guangdong 516000)

机构地区：[1]广东省惠州市博罗县人民医院肿瘤科,广东惠州516000

出　　处：《当代医药论丛》2022年第14期41-44,共4页

基　　金：惠州科技局立项,编号:210426104574691。

摘　　要：目的:探讨为接受化疗的恶性肿瘤患者应用二级预防药物对其中性粒细胞减少症发生率的影响。方法:选择近年来在惠州市博罗县人民医院进行化疗的46例恶性肿瘤患者作为研究对象。按照预防用药方案的不同将其分为Ⅰ组和Ⅱ组。Ⅰ组患者在化疗期间通过口服地榆升白片来预防中性粒细胞减少症的发生,Ⅱ组患者在化疗期间通过皮下注射重组人粒细胞刺激因子来预防中性粒细胞减少症的发生。比较两组患者Ⅲ度以上中性粒细胞减少症的发生率、再次住院率、抗菌药物的使用率、发热性中性粒细胞减少症的发生率、化疗周期天数及不良反应发生率。结果:干预后,两组患者Ⅲ度以上中性粒细胞减少症的发生率、再次住院率、抗菌药物的使用率、发热性中性粒细胞减少症的发生率均较低,其化疗周期天数均在21 d左右。干预后,两组患者Ⅲ度以上中性粒细胞减少症的发生率、再次住院率、抗菌药物的使用率、发热性中性粒细胞减少症的发生率及化疗周期天数相比,P>0.05。用药后,两组患者不良反应的发生率相比,P>0.05。结论:在恶性肿瘤患者化疗期间,为其规范应用地榆升白片、重组人粒细胞刺激因子等二级预防药物能有效降低其中性粒细胞减少症的发生率、再次住院率及抗菌药物的使用率,且用药的安全性较高。Objective:To investigate the effect of secondary prophylactics on the incidence of neutropenia in patients with malignant tumor undergoing chemotherapy.Methods:46 patients with malignant tumor who received chemotherapy in Boluo County People’s Hospital of Huizhou in recent years were selected as the research object.According to the different prophylactic drug regimen,they were divided into groupⅰand groupⅱ.Patients in groupⅰwere given oral Diyushengbai tablets to prevent neutropenia during chemotherapy,and patients in groupⅱwere given subcutaneous injection of recombinant human granulocyte-stimulating factor to prevent neutropenia dur ing chemotherapy.The incidence of neutropenia above gradeⅲ,the rate of re-hospitalization,the utilization rate of antibiotics,the incidence of febrile neutropenia,the number of chemotherapy cycles and the incidence of adverse reactions were compared between the two groups.Results:After intervention,the incidence of neutropenia above gradeⅲ,re-hospitalization rate,the utilization rate of antibiotics,and the incidence of febrile neutropenia were lower in both groups,and the days of chemotherapy cycle were about 21 days.After intervention,the incidence of neutropenia above gradeⅲ,the rate of re-hospitalization,the utilization rate of antibiotics,the incidence of febrile neutropenia and the days of chemotherapy were compared between the two groups,P>0.05.After medication,the incidence of adverse reactions in 2 groups was compared,P>0.05.Conclusion:The standardized application of secondary preventive drugs such as Diyushengbai tablet and recombinant human granulocyte-stimulating factor can effectively reduce the incidence of neutropenia,re-hospitalization rate and utilization rate of antibiotics in patients with malignant tumor during chemotherapy,and the safety of medication is high.

关 键 词：恶性肿瘤 二级预防药物 中性粒细胞减少症 地榆升白片 重组人粒细胞刺激因子 不良反应 

分 类 号：R730.4[医药卫生—肿瘤]